NAMS
NewAmsterdam Pharma Company N.V. · Healthcare
Chief Scientific Officer Johannes Jacob Pieter Kastelein sold $1.6M of NewAmsterdam Pharma Company N.V.
Sold$1,605,998
$35.31Price
45,481Shares
−46%Stake
What NAMS did after the filing
- The stock from Tue, Feb 24 close, $36.01
- −5.6%
- S&P 500, same days
- −1.6%
Measured over 30 trading days, to the Apr 8 close.
Traded Fri, Feb 20. Filed Tue, Feb 24, 11:40 AM ET, during the session. Returns use the Feb 24 close and the Apr 8 close. Not investment advice.